Inapill

Executive Summary

Inapill is a preclinical-stage biotech company pioneering first-in-class, orally available small molecules that target immunometabolism to treat inflammatory, autoimmune, and age-related diseases. Founded in 2020 and based in San Francisco, the company aims to address the limitations of current biologic therapies—such as high cost, injection burden, and immunosuppressive side effects—by modulating upstream metabolic pathways in immune cells. Its platform has the potential to unlock a new class of disease-modifying therapies with improved safety, convenience, and patient adherence. With a focus on well-validated targets in immunometabolism, Inapill is positioned to capture significant market share in large therapeutic areas like rheumatoid arthritis, psoriasis, and neurodegenerative conditions. While Inapill remains in the preclinical phase with no disclosed pipeline or funding rounds, the company is expected to advance its lead candidates toward IND-enabling studies over the next 12–18 months. The immunometabolism field is gaining traction, and a successful financing round or positive preclinical data could serve as major value inflections. With an experienced management team and a differentiated approach, Inapill represents an early-stage opportunity in a high-potential space, though it carries inherent risks typical of preclinical development.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement70% success
• Q4 2026Presentation of Preclinical In Vivo Efficacy Data at Major Immunology Conference80% success
• Q2 2027Filing of IND for Lead Candidate50% success